Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Lithium Salicylate · AL001

Small molecule · developed by Alzamend Neuro

Phase 1/2 Most advanced trial
ALZN Developer
1 Registered trials

What is Lithium Salicylate?

Lithium Salicylate is an investigational small-molecule drug studied in Bipolar I Disorder.

At a glance

Also known as
AL001
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Alzamend Neuro, Inc. (ALZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
93F1SP6QIN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07540338 Phase 1/2 Bipolar I Disorder Recruiting ALZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bipolar I Disorder

More from Alzamend Neuro

ALZN002 Phase 1/2

Follow ALZN, the company behind Lithium Salicylate

See ALZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.